News Release
January 2013
CET Announcing Products for IPS Cell Lines.
CET now offers several IPS cell lines for research applications. Using our proprietary technology these cell lines have been created using our novel viral-based gene constructs that contains modified Yamanaka factors with different protein structures. IPS cells were created by reprogramming the following target cells: Human Foreskin Fibroblast, Cord blood multipotent stem cell and Alzheimer Disease with Presenillin-1 mutation. For further details, please see our product page for these cell lines.
January 2013
CET Announces New Stem Cell Biobank Partnership to Accelerate Drug Discovery.
Cellular Engineering Technologies Inc. (CET), a stem cell biotech company, and the non-profit John Paul II Medical Research Institute (JP2MRI) announce a partnership to develop a private stem cell biobank. CET, a biomanufacturer of human stem cells, is collaborating with the JP2MRI to create over 5,000 patient and disease-specific stem cell lines and other human cell lines to advance drug discovery, offer personalized medicine, and biomanufacturing. These cell lines are derived from adult sources and do not include embryonic stem cells.
A stem cell biobank will help overcome the greatest obstacle to offering personalized medicine and will accelerate the search for effective treatments. It will do so by enabling drug testing on patient specific stem cells, in contrast to the currently used models involving animal testing and clinical trials that are vastly more expensive and time consuming. The biobank stem cell lines will serve as models to better predict the outcome of drug therapy in patients and dramatically advance research to bring new treatments to market sooner and at less cost.
The CET and JP2MRI partnership will eliminate the barriers that typically impact government and academic biobanks because stem cell donations will come directly from patients recruited from private practice doctors and private hospitals. The Institute has launched its Give Cures program that has created a network of doctors in several private clinics and hospitals around the country to recruit patients to procure tissue to create the stem cell lines.
Download the news release to read the strory.
October 2012
CET now provides customize induced pluripotent stem (IPS) cell reprograming service and products.
May 2012
Cellular Engineering Technologies, Inc. (CET) now offers patients-specific Human Bronchial Epithelial cells.
May 2012
Cellular Engineering Technologies, Inc. (CET) now offers Human Foreskin Fibroblast (HFF) and Keratinocyte cells.
November 2010
Federal Grant to Fund Acceleration of New Treatments for Rare Orphan Diseases.
Coralville, IA--Cellular Engineering Technologies (CET) Inc., a Coralville, Iowa, Biotechnology Company that develops commercial regenerative medicine products is one of 32 U.S. biotechnology companies that recently received a Federal grant from the Qualifying Therapeutic Discovery Project that was created by Congress. The purpose of the grant issued to CET will help to support the development of platform technologies in regenerative medicine and to accelerate discovery of new treatments for rare orphan diseases like Cystic Fibrosis, Muscular Dystrophy, Autism, Alpha 1 Anti-Trypsin Deficiency, Cystinosis and Lysosomal Storage Diseases.
September 2010
CET Announces An NIH Intramalls Vendor.
CET is happy to announce that it is now an NIH Intramalls vendor. If you are a researcher at the NIH, FDA or USDA, please login to your Intramalls account and browse our discounted product offerings. To enter the Intramalls site visit http://www.intramalls.com.
May 2010
CET Announces A Comprehensive Product Line.
CET is happy to announce a comprehensive product line for all your primary and stem cell needs. From growth and differentiation media, to a wide variety cells, we've got you covered. If you don't see something you like, contact us and we can try to assist you. Now, for a limited time, we are offering a 15% discount if you order from our website. Please refer to the pdf attachments for product descriptions and pricing. If you have any questions, please email us at orders@celleng-tech.com.
March 2010
Cellular Engineering Technology Receives DEMO Fund Grant from the Iowa Department of Economic Development (IDED) to Develop Novel Induced Pluripotent Stem Cells.
Cellular Engineering Technologies Inc Receives 2009 Best of Business Award From Small Business Commerce Association.
The Small Business Commerce Association (SBCA) announce that Cellular Engineering Technologies Inc has been selected for the 2009 Best of Business Award in the Biotechnology, Commercial category. The SBCA 2009 Award Program recognizes the top 5% of small businesses throughout the country. For further details of this award, see the below link.
http://www.smallbusinesscommerceassociation.org/PressRelease/AV5WBZ
Social Media Links:
